Effects of the Magenstrasse and Mill operation for obesity on plasma plasminogen activator inhibitor type 1, tissue plasminogen activator, fibrinogen and insulin

被引:7
|
作者
Carmichael, AR
Tate, G
King, RFG
Sue-Ling, HM
Johnston, D
机构
[1] Leeds Gen Infirm, Acad Dept Surg, Leeds, W Yorkshire, England
[2] Leeds Gen Infirm, Dept Haematol, Leeds, W Yorkshire, England
关键词
obesity; fibrinolysis; fibrinogen; insulin;
D O I
10.1159/000057287
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Plasminogen activator inhibitor 1 (PAI-1), tissue plasminogen activator (t-PA), fibrinogen and insulin were measured in 43 patients 3 years after they had undergone the Magenstrasse and Mill (MM) procedure and in 43 morbidly obese (MO) patients. Mean plasma PAI-1 was 61 ng/ml in the MO group compared to 30 ng/ml in the MM group (p < 0.0001); mean plasma t-PA was 10 ng/ml in the MO group compared to 7 ng/ml in the MM group (p < 0.001). Mean fibrinogen was 3.6 g/l in the MO group compared to 3.2 g/l in the MM group (p < 0.05). Mean plasma insulin levels were 32 U/ml in the MO group compared to 15 U/ml in the MM group. These changes suggest that use of the MM procedure may reduce mortality and morbidity from coronary heart disease in these high-risk obese patients. Copyright (C) 2002 S. Karger AG, Basel.
引用
收藏
页码:40 / 43
页数:4
相关论文
共 50 条
  • [31] Tissue plasminogen activator and plasminogen activator inhibitor-1 in human choledochal bile
    Lee, SJ
    Cho, JS
    Chung, JP
    Lee, KS
    Chung, JB
    Lee, SI
    Moon, YM
    Kang, JK
    Park, IS
    GASTROENTEROLOGY, 1999, 116 (04) : A19 - A19
  • [32] Secretion of tissue plasminogen activator and plasminogen activator inhibitor 1 during cardiopulmonary bypass
    Chandler, WL
    Velan, T
    THROMBOSIS RESEARCH, 2003, 112 (03) : 185 - 192
  • [33] Effect of Tisseel® on expression of tissue plasminogen activator and plasminogen activator inhibitor-1
    Diamond, MP
    Kruger, M
    Saed, GM
    FERTILITY AND STERILITY, 2004, 81 (06) : 1657 - 1664
  • [35] BIOLOGICAL EFFECTS OF INACTIVATION OF THE GENES FOR TISSUE-TYPE PLASMINOGEN-ACTIVATOR, UROKINASE-TYPE PLASMINOGEN-ACTIVATOR AND PLASMINOGEN-ACTIVATOR INHIBITOR-1 IN MICE
    CARMELIET, P
    SCHOONJANS, L
    KIECKENS, L
    STASSEN, JM
    BRONSON, R
    COLLEN, D
    MULLIGAN, R
    FIBRINOLYSIS, 1993, 7 : 27 - 28
  • [36] BIOLOGICAL EFFECTS OF DISRUPTION OF THE TISSUE-TYPE PLASMINOGEN-ACTIVATOR, UROKINASE-TYPE PLASMINOGEN-ACTIVATOR, AND PLASMINOGEN-ACTIVATOR INHIBITOR-1 GENES IN MICE
    CARMELIET, P
    BOUCHE, A
    DECLERCQ, C
    JANSSEN, S
    POLLEFEYT, S
    WYNS, S
    MULLIGAN, RC
    COLLEN, D
    ATHEROSCLEROSIS III: RECENT ADVANCES IN ATHEROSCLEROSIS RESEARCH: THE THIRD SARATOGA INTERNATIONAL CONFERENCE ON ATHEROSCLEROSIS IN NEKOMA, 1995, 748 : 367 - 382
  • [37] TISSUE-TYPE PLASMINOGEN-ACTIVATOR, TYPE-1 PLASMINOGEN-ACTIVATOR INHIBITOR AND THEIR COMPLEX IN PLASMA WITH DISSEMINATED INTRAVASCULAR COAGULATION
    FUKAO, H
    UESHIMA, S
    OKADA, K
    YAMAMOTO, K
    MATSUO, T
    MATSUO, O
    THROMBOSIS RESEARCH, 1992, 68 (01) : 57 - 65
  • [38] Role of tissue-type plasminogen activator and plasminogen activator inhibitor-1 in psychological stress and depression
    Tsai, Shih-Jen
    ONCOTARGET, 2017, 8 (68) : 113258 - 113268
  • [39] Increased plasminogen activator inhibitor-1/tissue type plasminogen activator ratio in oral submucous fibrosis
    Yang, S-F
    Hsieh, Y-S
    Tsai, C-H
    Chen, Y-J
    Chang, Y-C
    ORAL DISEASES, 2007, 13 (02) : 234 - 238
  • [40] TISSUE-TYPE PLASMINOGEN-ACTIVATOR AND PLASMINOGEN-ACTIVATOR INHIBITOR IN RAYNAUD PHENOMENON
    SILVERI, F
    SERRETTI, R
    CORE, P
    BRECCIAROLI, D
    THROMBOSIS RESEARCH, 1993, 70 : S93 - S93